The second phase 2 trial NCT02228681 evaluated the effectiveness of the mTOR inhibitor Everolimus (10 mg/day) and Letrozole (2.5 mg/day) compared with Tamoxifen (20 mg/day) and Medroxyprogesterone acetate (200 mg/day) and severity of side effects in 74 women with advanced, recurrent or persistent endometrial cancer (FIGO stage III or IV). This evidence concerns the gene MTOR and endometrial cancer.